Capsid Tropism Screening Platforms Market Report 2026

Capsid Tropism Screening Platforms Market Overview

• Capsid Tropism Screening Platforms market size has reached to $0.74 billion in 2025 • Expected to grow to $1.45 billion in 2030 at a compound annual growth rate (CAGR) of 14.4% • Growth Driver: The Rise In Demand For Targeted Gene Therapies Driving The Growth Of The Market Due To Increasing Prevalence Of Genetic Disorders • Market Trend: Strategic Partnerships Drive Innovation In High-Throughput Gene Therapy Screening • Asia-Pacific was the largest region and fastest growing region.

What Is Covered Under Capsid Tropism Screening Platforms Market?

Capsid tropism screening platforms refers to specialized tools and technologies used to evaluate and identify the specific tissue or cell types that viral capsids can efficiently target and enter. These platforms enable researchers to optimize viral vectors for gene therapy by assessing their delivery efficiency, specificity, and safety across different biological environments. The main technologies of capsid tropism screening platforms include high-throughput screening, next-generation sequencing, flow cytometry, and other technologies. High-throughput screening refers to advanced methods used to rapidly evaluate capsid variants for tissue targeting efficiency and specificity. The product types include assay kits, reagents, instruments, software, and services. The various applications involved are gene therapy development, vaccine development, drug discovery, and other applications, and they are used by several end users such as pharmaceutical and biotechnology companies, academic and research institutes, contract research organizations, and other end-users.

What Is The Capsid Tropism Screening Platforms Market Growth Forecast?

The capsid tropism screening platforms market size is expected to see rapid growth in the next few years. It will grow to $1.45 billion in 2030 at a compound annual growth rate (CAGR) of 14.4%. The growth in the forecast period can be attributed to growing use of AI-driven capsid tropism analysis, increasing deployment of high-content imaging and microfluidics, rising demand for single-cell sequencing and advanced screening platforms, expansion of contract research organizations (CROs), increasing integration of multiplex assay and digital PCR technologies. Major trends in the forecast period include increasing adoption of high-throughput screening platforms, rising demand for next-generation sequencing solutions, growing integration of flow cytometry technologies, expansion of assay kits and reagent offerings, rising focus on gene therapy and vaccine development applications.

Global Capsid Tropism Screening Platforms Market Segmentation

1) By Technology: High-Throughput Screening, Next-Generation Sequencing, Flow Cytometry, Other Technologies 2) By Product Type: Assay Kits, Reagents, Instruments, Software, Services 3) By Application: Gene Therapy Development, Vaccine Development, Drug Discovery, Other Applications 4) By End-User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Contract Research Organizations, Other End-Users Subsegments: 1) By High-Throughput Screening: Cell-Based Screening, Biochemical Screening, High-Content Screening, Automated Screening, Label-Free Screening 2) By Next-Generation Sequencing: Short-Read Sequencing, Long-Read Sequencing, Targeted Sequencing, Whole-Genome Sequencing, Single-Cell Sequencing 3) By Flow Cytometry: Conventional Flow Cytometry, Spectral Flow Cytometry, Imaging Flow Cytometry, Cell Sorting, Mass Cytometry 4) By Other Technologies: Microfluidics-Based Screening, High-Content Imaging, Mass Spectrometry, Polymerase Chain Reaction And Digital Polymerase Chain Reaction, Immunoassay-Based Platforms

What Is The Driver Of The Capsid Tropism Screening Platforms Market?

The increasing demand for targeted gene therapies is expected to drive the growth of the capsid tropism screening platforms market over the forecast period. Targeted gene therapies involve delivering therapeutic genetic material to specific cells or tissues to correct, modify, or replace defective genes responsible for disease. The rising demand for these therapies is driven by multiple factors, including the growing prevalence of genetic and rare diseases, advances in vector engineering technologies, and increased investment in precision medicine approaches that aim to improve treatment efficacy while minimizing off-target effects. Capsid tropism screening platforms play a critical role in gene therapy development by enabling the systematic evaluation and selection of viral vectors with optimal tissue and cell specificity. For instance, in January 2024, according to the American Society of Gene & Cell Therapy, a US-based organization for gene and cell therapy, the number of gene therapies in Phase III clinical trials increased by 10% in the fourth quarter of 2023, representing the first quarterly increase since the third quarter of 2022. Therefore, the increasing demand for targeted gene therapies is driving the growth of the capsid tropism screening platforms industry.

Key Players In The Global Capsid Tropism Screening Platforms Market

Major companies operating in the capsid tropism screening platforms market are Sarepta Therapeutics Inc., Voyager Therapeutics Inc., Bluebird Bio Inc., Sangamo Therapeutics Inc., REGENXBIO Inc., MeiraGTx Holdings plc, Dyno Therapeutics Inc., 4D Molecular Therapeutics Inc., Asklepios BioPharmaceutical Inc., PackGene Biotech Inc., Creative Biolabs Inc., VectorBuilder Inc., uniQure N.V., Homology Medicines Inc., Capsida Biotherapeutics Inc., LogicBio Therapeutics Inc., Capsigen Inc., GeneMedi Inc., Spark Therapeutics Inc., Creative Biogene Inc.

Global Capsid Tropism Screening Platforms Market Trends and Insights

Major companies operating in the capsid tropism screening platforms market are forming strategic partnerships to develop innovative high-throughput and barcoded adeno-associated virus screening solutions. Strategic partnerships propel the growth of the capsid tropism screening platforms market by enabling collaborative development of advanced adeno-associated virus screening technologies, expanding product portfolios, and accelerating gene therapy research and commercialization. For instance, in August 2025, PackGene Biotech Inc., a US-based biotechnology company, entered a strategic licensing agreement with the Children’s Medical Research Institute (CMRI), an Australia-based independent organization, to commercialize barcoded high-throughput adeno-associated virus capsid screening kits. These kits enable researchers to rapidly evaluate multiple adeno-associated virus capsid variants simultaneously using a barcode system and next-generation sequencing. The collaboration aims to accelerate gene therapy development by streamlining capsid selection and improving access to advanced screening tools.

What Are Latest Mergers And Acquisitions In The Capsid Tropism Screening Platforms Market?

In April 2023, Ginkgo Bioworks Holdings Inc., a US-based synthetic biology platform company, acquired adeno-associated virus capsid discovery and engineering platform assets from StrideBio for an undisclosed amount. With this acquisition, Ginkgo Bioworks aims to enhance its technological capabilities in viral vector design and capsid tropism screening, strengthening its position in the gene therapy market. StrideBio Inc. is a US-based provider of advanced adeno-associated virus capsid discovery and engineering technologies that enable optimized tissue-specific delivery for gene therapies.

Regional Insights

North America was the largest region in the capsid tropism screening platforms market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Capsid Tropism Screening Platforms Market?

The capsid tropism screening platforms market consists of revenues earned by entities by providing services such as tissue-specific tropism analysis, high-throughput viral vector profiling, preclinical vector optimization studies, custom assay development for capsid targeting, and cell type-specific transduction efficiency testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The capsid tropism screening platforms market also includes sales of high-throughput screening kits, reporter assays, cell panels, bioinformatics tools, and next-generation sequencing (ngs) kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data And Analysis Are Included In The Capsid Tropism Screening Platforms Market Report 2026?

The capsid tropism screening platforms market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the capsid tropism screening platforms industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.